Genome of a midsection Holocene huntergatherer coming from Wallacea

The Behavior and Neuroimaging Core provides project-specific collaboration and support to COBRE scientists to promote the acquisition of high quality behavioral, physiological, neuroimaging and neurostimulation data, to ensure the integrity of the data collection infrastructure and to help implement robust data processing and visualization pipelines. While the cores principally serve Center scientists, our Center and the core resources have availability to all Rhode Island researchers.The COBRE for Perinatal Biology (CPB) was the third grant in Rhode Island to be funded by the COBRE mechanism. The CPB was based at Women & Infants Hospital, and housed in the Kilguss Research Institute, in the Jewelry District in Providence. The scientific focus of the CPB was on perinatal diseases such as preeclampsia and preterm birth, as well as more broadly on cardiopulmonary development and reproductive biology. Over the course of three phases and 17 years, the CPB funded 22 projects. CPB investigators, in turn, generated over $27.5 million in independent funding from federal and non-federal sources. check details Besides providing scientific and career mentorship to new investigators in Rhode Island, the CPB established a Research Core. The Kilguss Research Core remains active and flourishing and provides advanced imaging, molecular biology and flow cytometry abilities to researchers at Women & Infants as well as the greater Rhode Island scientific community.The Center for Addiction and Disease Risk Exacerbation (CADRE) is a COBRE establishing a thematically linked, state-of-the-art, multidisciplinary Center investigating mechanisms where-by substance use (SU) increases the risk for or exacerbates chronic disease. It does so by employing a combination of behavioral and physiological laboratory-based approaches across several substances and across several diseases. COBRE projects investigate mechanisms underlying effects of opioids, cannabis, tobacco, and alcohol on risks for and progression of SU-related disease. Though linkages between SU and disease are well documented, physiological mechanisms underlying such associations are poorly understood, mainly because published studies use cross-sectional designs that do not allow for causal interpretations. Mechanisms studied in CADRE projects include systemic inflammation, immune system dysregulation, high blood pressure, pulmonary effects, and carcinogen exposure. A Clinical Laboratory Core provides infrastructure, resources, and scientific expertise and a center-wide database of risk factors associated with the development of SU and chronic disease.Overdose deaths across the country have spiked since the onset of the COVID-19 pandemic. It is crucial now, more than ever, to address the continuing and worsening, complex and dynamic opioid and overdose epidemics. In 2018, The Center of Biomedical Research Excellence (COBRE) on Opioids and Overdose, based at Rhode Island Hospital, launched with three major goals 1) establish a center of scientific excellence on opioids and overdose; 2) train the next generation of scientists to become independent investigators and address the opioid and overdose crises; and 3) contribute to the scientific progress and solutions to combat these epidemics. To date, we have made substantial progress. While the opioid and overdose crises continue to evolve, the COBRE on Opioid and Overdose and its team of investigators are well poised to address the daunting task of understanding and meaningfully addressing these deadly epidemics, with the ultimate goal of saving lives.The opioid epidemic has reached into all aspects of life in the United States. The epidemic has crossed racial, economic, social, and generational barriers. This epidemic also impacts infants. Fetal exposure to opioids can produce a withdrawal effect in newborns, referred to as Neonatal Opioid Withdrawal Syndrome (NOWS). NOWS treatment lacks a standard approach, with prominent variation across the United States. Furthermore, many treatment strategies for NOWS are not evidence-based but reflect anecdotal experience. Variable approaches to NOWS treatment contribute to more extended hospital stays and greater postnatal opioid exposure. The most prolonged period of NOWS treatment occurs during the weaning phase. This paper describes the first prospective randomized control trial to address systematized weaning of opioids for infants with NOWS.
Peripherally inserted central catheter (PICC) use among critically ill patients with or without acute kidney injury (AKI) has gradually increased. Ultrasound-guided bedside PICC insertion in intensive care units (ICU) has been reported to be safe and effective. Reports of PICC insertion by a nephrologist without fluoroscopy, however, are relatively rare.
This retrospective study included patients (n = 224) who had a PICC inserted by a single nephrologist at Samsung Changwon Hospital from January 2019 to June 2020. Group 1 patients (n = 98) had PICCs inserted under ultrasound guidance, while group 2 patients (n = 126) had PICCs inserted under fluoroscopic guidance. Success rates, multiple puncture rates, and malposition rates were compared between the two groups.
Underlying comorbidities (sepsis, AKI, ventilator use, and shock) were more common in group 1 than in group 2. Success rates were comparable between the two groups (93.9% vs. 97.6%, P = 0.171). Multiple puncture rate among successful cases (4.1% vs. 0.0%, P = 0.035) was higher in group 1 than group 2. Excluding central vein occlusion cases, malposition occurred only one in group 1.
Bedside PICC insertion by a nephrologist is easy and safe to perform in comorbid patients who are difficult to move to the angiography room. The success rate of ultrasound-guided PICC insertions was comparable to that of PICC insertion performed under fluoroscopic guidance. In the life-threatening ICU setting, PICCs can be successfully placed by the interventional nephrologists.
Bedside PICC insertion by a nephrologist is easy and safe to perform in comorbid patients who are difficult to move to the angiography room. The success rate of ultrasound-guided PICC insertions was comparable to that of PICC insertion performed under fluoroscopic guidance. In the life-threatening ICU setting, PICCs can be successfully placed by the interventional nephrologists.